无创纤维化模型检测纤维化分期变化的诊断准确性
该研究回顾性分析美国NIDDK NASH临床研究网络2004至2018年数据,在1904例横断面受试者中以活检为参考标准评估APRI、FIB-4、AST:ALT比值和NFS对非酒精性脂肪性肝病(NAFLD)肝纤维化的诊断性能,并在292例有2次活检的纵向数据集中评估模型检测纤维化分期变化的能力;FIB-4和NFS检测进展期纤维化优于其他模型,APRI、FIB-4和NFS的变化与纤维化变化显著相关,可检测纤维化进展。
要点
- 横断面研究中,FIB-4和NFS检测进展期纤维化的C统计量分别为0.80和0.78,优于其他无创模型。
- 纵向研究中,APRI、FIB-4和NFS每变化1个单位与纤维化分期变化分别相关0.33、0.26和0.19。
- APRI、FIB-4和NFS检测进展至进展期纤维化的交叉验证C统计量分别为0.82、0.81和0.80。
核心结论
- 在两项大型研究数据的联合分析中,FIB-4、APRI和NFS可检测NAFLD患者的进展期纤维化和纤维化进展。
研究设计与样本
- 回顾性分析美国NIDDK NASH临床研究网络2004至2018年入组个体数据,以活检为参考标准。
- 横断面研究纳入1904例受试者,评估APRI、FIB-4、AST:ALT比值和NFS的诊断性能。
- 纵向数据集纳入292例有2次活检及配套实验室数据的受试者,评估模型检测纤维化分期变化的能力。
主要发现
- 横断面研究中,FIB-4和NFS检测进展期纤维化优于其他无创模型,C统计量FIB-4为0.80、NFS为0.78。
- 纵向研究中,216例基线为非进展期纤维化,中位随访2.6年后35例进展为进展期纤维化。
- 调整初次活检纤维化分期和模型评分后,APRI、FIB-4和NFS的变化与纤维化变化显著相关。
- APRI、FIB-4和NFS每变化1个单位与纤维化分期变化分别相关0.33(95%CI 0.20-0.45;P<.001)、0.26(95%CI 0.15-0.37;P<.001)和0.19(95%CI 0.07-0.31;P=.002)。
- 检测进展至进展期纤维化的交叉验证C统计量:APRI为0.82(95%CI 0.74-0.89),FIB-4为0.81(95%CI 0.73-0.81),NFS为0.80(95%CI 0.71-0.88)。
关键数值与推荐
- 横断面研究检测进展期纤维化:FIB-4的C统计量为0.80,NFS的C统计量为0.78。
- 纵向研究检测进展至进展期纤维化:APRI的交叉验证C统计量为0.82(95%CI 0.74-0.89),FIB-4为0.81(95%CI 0.73-0.81),NFS为0.80(95%CI 0.71-0.88)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Noninvasive methods are needed to determine disease stage in patients with nonalcoholic fatty liver disease (NAFLD). We evaluated the diagnostic performance of several widely available fibrosis models for the assessment of hepatic fibrosis in patients with NAFLD. METHODS: We performed a retrospective analysis of data from individuals enrolled in the NIDDK NASH Clinical Research Network, from 2004 through 2018. Using biopsy as the reference standard, we determined the diagnostic performance of the aspartate aminotransferase (AST):platelet ratio (APRI), FIB-4, ratio of AST:alanine aminotransferase (ALT) and the NAFLD fibrosis score (NFS) in a cross-sectional study of 1904 subjects. The ability of these models to detect changes in fibrosis stage was assessed in a longitudinal data set of 292 subjects with 2 biopsies and accompanying laboratory data. Outcomes were detection of fibrosis of any stage (stages 0-4), detection of moderate fibrosis (stages 0-1 vs 2-4), and detection of advanced fibrosis (stages 0-2 vs 3-4). Diagnostic performance was evaluated using the C-statistic, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) analyses. RESULTS: In the cross-sectional study, FIB-4 and NFS outperformed other non-invasive models for detecting advanced fibrosis; the C-statistics were 0.80 for FIB-4 and 0.78 for NFS. In the longitudinal study, 216 patients had non-advanced fibrosis at baseline and 35 patients progressed to advanced fibrosis after median follow up of 2.6 years. After we adjusted for fibrosis stage and model score at initial biopsy, change in APRI, FIB-4, and NFS were significantly associated with change in fibrosis. A unit change in APRI, FIB-4, or NFS was associated with changes in fibrosis stage of 0.33 (95% CI, 0.20-0.45; P < .001), 0.26 (95% CI, 0.15-0.37; P < .001), and 0.19 (95% CI, 0.07-0.31; P = .002), respectively. The cross-validated C-statistic for detecting progression to advanced fibrosis for APRI was 0.82 (95% CI, 0.74-0.89), for FIB-4 was 0.81 (95% CI, 0.73-0.81), and for NFS was 0.80 (95% CI, 0.71-0.88). CONCLUSIONS: In a combined analysis of data from 2 large studies, we found that FIB-4, APRI, and NFS can detect advanced fibrosis and fibrosis progression in patients with NAFLD.
引用
- Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. Clin Gastroenterol Hepatol. 2019. PMID: 30616027. doi:10.1016/j.cgh.2018.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。